CagriSema Phase 3 Results: 20% Weight Loss in REDEFINE Trials, Novo Nordisk Files for FDA Approval

The REDEFINE 1 trial is the largest and most important study in the CagriSema program — a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the combination in adults with obesity or overweight without type 2 diabetes.

Study design. A total of 3,417 participants were randomized: 2,108 to CagriSema, 302 to semaglutide alone, 302 to cagrilintide alone, and 705 to placebo. The primary endpoint was percentage change in body weight from baseline to week 68. Results were published in the New England Journal of Medicine.

Weight loss results. CagriSema produced a mean weight loss of 20.4% at 68 weeks, compared to 3.0% with placebo. This places CagriSema in the same efficacy range as the highest doses of tirzepatide (20–22% in SURMOUNT trials) and substantially above semaglutide monotherapy (approximately 15% in STEP trials).

Responder analysis. The responder rates are particularly striking: 60% of CagriSema participants achieved at least 20% weight loss, and 23% achieved at least 30% weight loss. These are the highest responder rates in any published Phase 3 obesity trial. For context, tirzepatide’s highest responder rates in SURMOUNT-1 were approximately 57% achieving 20% or more weight loss.

The combination advantage. Semaglutide and cagrilintide individually produce meaningful weight loss, but their combination produces results that exceed either component alone. This demonstrates genuine synergy between the GLP-1 and amylin pathways — supporting the hypothesis that targeting multiple appetite-regulation mechanisms simultaneously produces superior outcomes.

The REDEFINE 2 trial evaluated CagriSema specifically in adults with obesity or overweight and type 2 diabetes — a population that typically shows less weight loss with GLP-1 drugs compared to non-diabetic populations.

Dual primary endpoints. The trial measured both HbA1c reduction and body weight change, reflecting the dual metabolic goals of treating patients with obesity and diabetes simultaneously.

HbA1c results. CagriSema produced a mean HbA1c reduction of 1.91 percentage points from baseline at 68 weeks — a clinically substantial improvement. This was statistically superior to semaglutide alone, demonstrating that the amylin component adds glycemic benefit beyond what GLP-1 agonism provides.

Weight loss results. Mean weight loss was 13.7% with CagriSema at 68 weeks, compared to 3.4% with placebo. While lower than the 20.4% seen in the non-diabetic population (consistent with all GLP-1 trials showing reduced weight loss in diabetes), 13.7% is still clinically meaningful and exceeds the typical results of semaglutide monotherapy in diabetic patients.

Comparison to semaglutide alone. The inclusion of a semaglutide-only arm in REDEFINE 2 provides the most direct evidence that the combination is superior to semaglutide monotherapy for both glycemic control and weight loss. This is the critical data point that supports CagriSema’s commercial positioning as a step up from Wegovy/Ozempic.

CagriSema’s safety profile is broadly consistent with the GLP-1 drug class but with higher gastrointestinal event rates attributable to the amylin component.

GI adverse events. In REDEFINE 1, gastrointestinal events occurred in 79.6% of CagriSema participants versus 39.9% with placebo. The most common were nausea, vomiting, diarrhea, constipation, and abdominal pain. The 79.6% rate is higher than the approximately 60–70% typically seen with semaglutide or tirzepatide monotherapy.

Severity and duration. Despite the higher frequency, GI events were mainly mild-to-moderate in severity and transient — concentrated during the dose-escalation period. The pattern is consistent with GLP-1 class drugs: GI symptoms are worst during titration and improve once patients reach their maintenance dose.

The amylin contribution. Cagrilintide, the amylin analog component, independently slows gastric emptying and promotes satiety — effects that overlap with semaglutide’s GI effects. The combination of two compounds that both affect gastric motility likely explains the higher GI event rate. Whether the additional GI burden is acceptable depends on whether patients prioritize maximum weight loss or minimum side effects.

Discontinuation rates. Detailed discontinuation data suggest that despite higher GI event rates, the overall tolerability is manageable for most patients — the 20%+ weight loss and the majority of participants completing the trial indicate that the benefit-risk balance was favorable in a clinical trial setting.

With CagriSema’s FDA filing and Phase 3 data now public, the competitive positioning is becoming clear.

Versus semaglutide (Wegovy). CagriSema is definitively superior for both weight loss and glycemic control. Novo Nordisk is positioning CagriSema as the natural upgrade for patients on Wegovy who want greater efficacy — and conveniently, both drugs come from the same manufacturer.

Versus tirzepatide (Zepbound). The comparison is closer. CagriSema’s 20.4% weight loss is in the same range as tirzepatide’s highest dose (20–22%). The responder rates (60% achieving 20%+ loss) may slightly favor CagriSema, but head-to-head data does not exist. The choice between these drugs will likely come down to side effect tolerance, pricing, and individual response.

Versus MariTide. MariTide offers monthly dosing versus CagriSema’s weekly, with similar weight loss (~20%). If both reach market, dosing frequency could be the deciding factor for many patients.

Versus Foundayo (orforglipron). CagriSema produces roughly double the weight loss of oral Foundayo (20% vs. 11%), but requires weekly injection versus daily oral dosing. For patients prioritizing maximum efficacy, CagriSema is the better choice. For patients prioritizing convenience and needle avoidance, Foundayo is preferred.

The Novo Nordisk strategy. CagriSema represents Novo Nordisk’s response to tirzepatide, which challenged semaglutide’s dominance with superior weight loss. By combining semaglutide with an amylin analog, Novo Nordisk has created a product that matches or exceeds tirzepatide’s efficacy while leveraging existing manufacturing and prescriber familiarity with semaglutide.

Novo Nordisk filed the CagriSema application with the FDA in December 2025, based on data from the REDEFINE 1 and REDEFINE 2 trials. Here is the expected path forward.

FDA review timeline. Standard review takes approximately 10–12 months from acceptance, placing a potential PDUFA (decision) date in late 2026 or early 2027. Priority review, if granted, could shorten this to approximately 6–8 months. Given the public health significance of obesity treatments and the robust Phase 3 data, priority review is plausible.

Manufacturing considerations. CagriSema is a fixed-dose combination injectable containing two biologic peptides. Manufacturing scale-up for combination products is more complex than single-agent products and requires dedicated production lines. Novo Nordisk has experience scaling semaglutide production but may face capacity constraints given simultaneous demand for Ozempic, Wegovy, and CagriSema.

Potential approval indication. The initial filing is for weight management (obesity/overweight with comorbidities), mirroring Wegovy’s indication. Type 2 diabetes indications would likely follow in a separate regulatory submission.

Impact on the market. CagriSema’s arrival would give Novo Nordisk a tirzepatide-competitive product while retaining patients within its ecosystem. Prescribers familiar with semaglutide dosing and management would have a natural upgrade path for patients seeking greater efficacy. The question is whether CagriSema’s higher GI side effect rate will limit its adoption compared to tirzepatide, which has a strong tolerability track record.